Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes

Hormone and Metabolic Research

Volumn 31, Issue 1, 1999, Pages 1-4

  Giorgini, A E ^a   Beales, P E ^a   Mire Sluis, A ^b   Scott, D ^b   Liddi, R ^a   Pozzilli, P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Cytokines; Troglitazone; Type 1 Diabetes

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKEMIA INHIBITORY FACTOR; PHYTOHEMAGGLUTININ; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERYTHROLEUKEMIA CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0032994819     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978686     Document Type: Article

References (14)

1. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996; 45: 1661-9
2. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, Haring H. Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes 1994; 43: 447-53
3. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-29
4. Sarvetnick N. Mechanisms of cytokine-mediated localized immunoprotection. J Exp Med 1996; 184: 1597-699
5. Hotamisligil GS, Speigelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8
6. Shimabukuro M, Koyama K, Lee Y, Unger RH. Leptin- or troglitazone-induced lipopenia protects islets from interleukin-1β cytotoxicity. J Clin Invest 1997; 100: 1750-4
7. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegilman BM. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance, and Endocrinology 1994; 134: 264-70
8. Ohsumi J, Sakakibara S, Yamaguchi J, Miyadai K, Yoshioka S, Fuliwara T, Horikoshi H, Serizawa N. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology 1994; 135: 2279-82
9. Beales PE, Liddi R, Giorgini AE, Signore A, Procaccini E, Batchelor K, Pozzilli P. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. European Journal of Pharmacology 1998; 357: 221-5
10. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF, Miyazono K, Urabe A, Takaku F. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, of erythropoietin. J Cell Physiol 1989; 140: 323-34
11. Meager A. A cytotoxicity assay for tumour necrosis factor using a human rhabdomyosarcoma cell line. J Imm Methods 1991; 144: 141-3
12. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin-10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991; 173: 507-10
13. Mire-Sluis A, Wickremasinghe RG, Hoffbrand AV, Timms AM, Francis GE. Human T lymphocytes stimulated by phytohaemagglutinin undergo a single round of cell division without a requiremement for interleukin-2 or accessory cells. Immunology 1987; 60: 7-12
14. Solimena M, De Camilli P. From Th-1 to Th-2: diabetes immunotherapy shifts gears. Nature Medicine 1996; 2: 1311-2